(MedPage Today) -- A hypertension self-management program reduced systolic blood pressure in high-risk patients, including those with cardiovascular disease, diabetes, or chronic kidney disease, according to British researchers.
BASEL (dpa-AFX) - Silence Therapeutics plc.(SLN.L) said that licence holder
Quark Pharmaceuticals Inc. has confirmed favourable results in its Phase 2 trial
for the use of QPI-1002 short interfering RNA or siRNA for the prevention of
Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its...
Atara Biotherapeutics Inc., a company in which Mexican billionaire Carlos Slim owns shares, filed for an initial public offering to expand kidney disease research - an illness that runs in the Slim family.